Development of a comprehensive microbial immunotherapy platform with immuno-transcriptomic monitoring for treatment of bladder cancer (DOCMI-BC)

开发用于治疗膀胱癌的具有免疫转录组监测的综合微生物免疫治疗平台（DOCMI-BC）

• 批准号: 10087336
• 金额: $ 25.55万
• 依托单位: PROKARIUM LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10087336
• 关键词: Development; comprehensive; microbial; immunotherapy; platform

Bladder Cancer (BC) affects more than 550,000 people globally every year. With the highest recurrence rate of any known cancer (80%), it is one of the most expensive for the NHS to treat, costing £65M pa (CRUK). Current immunotherapy treatments based on the weakened strain of _Mycobacterium bovis_ (BCG) present a significant challenge, with substantial impact on patient quality of life and high rates of cancer recurrence. Moreover, chemotherapy and other existing immunotherapies have significant side effects and generally poor response rates.Prokarium's therapeutics are positioned to overcome such limitations by leveraging the natural tumor-suppressive properties of proprietary _Salmonella_ bacteria strain ZH9\.Prokarium have previously shown that ZH9 has superior effectiveness compared to the current standard-of-care BCG in early-stage BC. This has enabled an upcoming first clinical trial and, in collaboration with Switzerland based University of Lausanne and Novigenix, Prokarium aims to expand upon this work to support the further development of ZH9 for BC by exploring the efficacy and mechanism of action of ZH9 in more advanced muscle invasive BC (MIBC), both as a standalone treatment and when administered in combination with other therapies, either already licensed or in development for BC.The incorporation of Novigenix technology will allow understanding of the mechanism of action of the therapy and identification of biomarkers of response that can be used to improve future clinical trials and ultimately provide better treatments to BC patients.

膀胱癌 (BC) 每年影响全球超过 550,000 人，其复发率是所有已知癌症中最高的 (80%)，也是 NHS 治疗费用最高的癌症之一，每年花费 6500 万英镑 (CRUK)。基于弱化牛分枝杆菌（BCG）菌株的免疫治疗提出了重大挑战，对患者的生活质量和癌症复发率产生了重大影响。此外，化疗和其他现有的治疗方法。免疫疗法具有显着的副作用，且反应率通常较差。Prokarium 的疗法旨在通过利用专有_沙门氏菌_菌株 ZH9\ 的天然肿瘤抑制特性来克服这些局限性。Prokarium 此前已表明，与当前标准相比，ZH9 具有卓越的有效性 - Prokarium 与瑞士洛桑大学和 Novigenix 合作，旨在扩大 BC 早期阶段的护理 BCG。这项工作旨在通过探索 ZH9 在更晚期肌肉侵袭性 BC (MIBC) 中的功效和作用机制，支持 ZH9 治疗 BC 的进一步开发，既可以作为独立治疗，也可以与其他疗法（已获得许可或正在申请中）联合使用。 BC 的开发。Novigenix 技术的结合将有助于了解治疗的作用机制并识别反应生物标志物，这些生物标志物可用于改进未来的临床试验，并最终为 BC 患者提供更好的治疗。